At the heart of smart manufacturing transforming medtech production is the data-driven approach. In a traditional manufacturing environment, data was often siloed, and problems were often only identified after a batch of products had already been completed. In a smart factory, every machine, sensor, and tool is connected to a central digital nervous system. This allows for real-time monitoring of the entire production process, from the temperature of a cleanroom to the precise force applied by a robotic assembly arm. This level of visibility is the essence of industry 4.0 healthcare, as it enables a proactive, predictive model where issues are identified and resolved before they ever lead to a defective product. This not only reduces waste and lowers costs but also significantly enhances the safety and reliability of the medical devices that reach the patient.

The Power of Digital Twins in MedTech Production

A cornerstone of smart manufacturing transforming medtech production is the use of digital twins. A digital twin is a virtual replica of a physical asset, whether it is a single machine, a production line, or an entire manufacturing facility. By creating these virtual models, medtech companies can simulate and optimize their production processes in a risk-free digital environment. For example, before a new surgical instrument goes into production, engineers can use a digital twin to test how different materials or manufacturing methods will affect its final quality and performance. This capability is a game-changer for digital twins production, as it drastically reduces the time and cost associated with prototyping and scaling up new innovations.

Furthermore, digital twins allow for a level of flexibility that is essential in the modern medtech landscape. As the industry moves toward more personalized and patient-specific devices, the ability to rapidly reconfigure a production line is a critical advantage. In a smart factory, a digital twin can be used to plan a seamless transition from one product variant to another, ensuring that the physical machines are updated with minimal downtime. This is particularly vital for the production of custom orthopedic implants or patient-specific surgical guides, where every unit is unique. By leveraging the power of smart manufacturing transforming medtech production, companies can now produce batches of one with the same efficiency and quality as mass-produced goods.

AI-Driven Quality Control and Predictive Maintenance

One of the most transformative aspects of smart manufacturing transforming medtech production is the integration of artificial intelligence into the quality control process. In traditional manufacturing, quality control often relies on manual inspections or statistical sampling, which can miss subtle defects. In contrast, an AI-driven system can use high-speed cameras and advanced image recognition to inspect every single unit on a production line in real-time. These AI systems can detect microscopic cracks, surface imperfections, or dimensional deviations that would be invisible to the human eye. This level of AI manufacturing healthcare is setting a new standard for precision and safety in the industry, ensuring that every device that leaves the factory is perfect.

Beyond quality control, AI is also revolutionizing the maintenance of manufacturing equipment. Predictive maintenance uses machine learning algorithms to analyze data from sensors on a machine to predict when it is likely to fail. This allows the manufacturer to perform maintenance during a planned shutdown, rather than waiting for a catastrophic failure that could halt production for days. For a medtech company, this reliability is essential, as even a short disruption in the supply of critical devices like heart valves or insulin pumps can have serious consequences for patient health. By integrating smart manufacturing transforming medtech production into their operations, companies are building a more resilient and dependable production ecosystem.

Automated Medical Manufacturing and Collaborative Robotics

The physical manifestation of smart manufacturing transforming medtech production is the rise of automated medical manufacturing. We are seeing a new generation of cobots, or collaborative robots, that are designed to work safely alongside human operators. Unlike traditional industrial robots that are often caged for safety, cobots use advanced sensors to detect human presence and can be easily programmed to assist with delicate tasks like the assembly of micro-fluidic devices or the packaging of sterile instruments. This human-robot collaboration is a hallmark of industry 4.0 healthcare, as it combines the dexterity and problem-solving skills of a human with the precision and tireless endurance of a machine.

The automation of the manufacturing process also extends to the smart logistics within the factory. Autonomous mobile robots (AMRs) can navigate a facility to deliver raw materials to a production line or move finished goods to a warehouse. This reduces the need for manual material handling and ensures that the production process flows smoothly and efficiently. This holistic approach to smart manufacturing transforming medtech production creates a seamless environment where every movement is optimized for maximum value. This efficiency is particularly important in a global market where medtech companies are facing increasing pressure to lower costs while maintaining the highest standards of quality and innovation.

Sustainability and the Future of Smart MedTech

As we look toward the future, smart manufacturing transforming medtech production will also play a key role in making the industry more sustainable. By optimizing energy use, reducing material waste, and improving the efficiency of the supply chain, smart factories can significantly lower their environmental footprint. This is becoming a major priority for both manufacturers and healthcare providers, as the global community works toward a greener healthcare system. Furthermore, the ability to produce devices closer to the point of care through localized, smart manufacturing hubs will reduce the carbon emissions associated with long-distance shipping.

The ultimate goal of smart manufacturing transforming medtech production is to create a more responsive and patient-centric healthcare system. We are moving toward a world where a patient’s unique anatomical data can be sent directly from a hospital to a smart factory, where a custom device is designed, manufactured, and shipped within 24 hours. This level of speed and personalization will revolutionize the treatment of complex conditions, from rare genetic disorders to traumatic injuries. By continuing to invest in the technologies of Industry 4.0, the medtech industry is not just changing how it makes things it is changing what is possible for the human body. The transformation is already underway, and the result will be a healthier, more precise, and more resilient world for everyone.

The Photonova Spectra platform is engineered to deliver broad coverage alongside ultra-high definition (UHD) spatial and spectral imaging. According to GE HealthCare, the system enables faster acquisition speeds and supports detailed visualization of subtle tissue variations, small lesions and vascular structures. Unlike conventional CT systems that convert X-rays into light before measurement, photon-counting CT directly detects individual X-ray photons and measures their energy. This approach allows for improved spatial and spectral resolution, as well as enhanced tissue characterization. The company also highlighted that its Deep Silicon detector material strengthens spectral imaging performance, particularly in lesion characterization and treatment monitoring. GE HealthCare submitted Photonova Spectra for FDA clearance in November 2025, incorporating advanced AI applications into the platform.

As clinicians across the United States face rising volumes and increasing diagnostic complexity, technology must do more than capture images it must simplify decision-making and strengthen performance across the enterprise, said Catherine Estrampes, President & CEO, U.S. and Canada, GE HealthCare. Photonova Spectra is designed to deliver rich clinical insights in every scan and help alleviate cognitive burden for care teams. With the U.S. 510(k) clearance, we are proud to now bring this innovation to U.S. healthcare systems and the patients they serve.

Further technical capabilities of Photonova Spectra include 8-bin energy resolution enabled by Deep Silicon, supporting advanced material separation and characterization. This allows clinicians to distinguish materials such as iodine, calcium and fat with greater clarity. The system’s wide detector coverage and rapid rotation speed of 0.23 seconds contribute to fast acquisition and motion-free imaging. Additionally, Photonova Spectra captures both 8-bin spectral and ultra-high definition spatial data simultaneously without requiring specialized protocols, ensuring spectral data is available in every exam.

GE HealthCare noted that the system has applications across neurology, oncology, musculoskeletal imaging, thoracic imaging and cardiology. It supports visualization of fine brain structures, characterization of lesions, detection of small fractures and bone marrow edema, and advanced cardiac and chest imaging. The platform also leverages Nvidia computing technology, enabling it to process up to 50 times more data than conventional CT systems. Ongoing collaborations with UW-Madison and Stanford Medicine are focused on exploring new clinical applications and imaging protocols. With regulatory approval in place, GE HealthCare is now preparing for commercial availability of Photonova Spectra in the U.S.

Photonova Spectra reflects years of intentional design and close collaboration with clinicians, researchers and collaborators across the globe, adds Jean-Luc Procaccini, president & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. From the earliest stages to today, we remain focused on building a system that addresses the practical realities of clinical practice while opening pathways for scientific advancement. The result is a photon-counting platform engineered for the needs of today’s care teams, as well as the imaging challenges and research opportunities that will shape the future of CT.

At the core of the platform is its ability to generate a patient-specific, simulation-ready digital replica of the lungs. By embedding directly into CT imaging workflows, the system uses deep learning models to reconstruct a detailed 3D digital twin, offering clinicians an interactive view of anatomical structures such as airways, blood vessels, lung lobes, and lesions. This AI Lung Digital Twin Platform enables practitioners to simulate bronchoscopy and biopsy pathways, facilitating improved procedural planning within an immersive digital environment.

The platform is built on NVIDIA Physical AI infrastructure, incorporating NVIDIA Omniverse and OpenUSD for interactive visualization, NVIDIA TensorRT for optimized AI inference, and NVIDIA MONAI for advanced image segmentation. These components collectively support automated identification of critical lung structures, volumetric analysis, and navigation path planning. By transforming static CT scans into dynamic models, the system allows clinicians to better assess anatomical relationships, reduce pre-operative planning time, and improve procedural safety across complex interventions.

“By combining LTTS’ engineering expertise in medical imaging and digital health platforms with the power of NVIDIA’s Physical AI infrastructure, we are enabling a new generation of AI-powered biological digital twins for precision medicine,” observed Amit Chadha, CEO & Managing Director, L&T Technology Services. “These platforms can transform how clinicians visualize lung anatomy, plan interventions and deliver precision care. The impact will be visible across the global healthcare ecosystem in the years ahead.”

David Niewolny, Head of Business Development for Healthcare and Medical Technology, NVIDIA, said, “Digital twins are emerging as a powerful new tool for precision medicine. By leveraging NVIDIA Physical AI infrastructure, Omniverse, MONAI and TensorRT, LTTS is transforming CT data into interactive lung digital twins that allow clinicians to visualize anatomy in 3D, simulate procedures and plan clinical interventions with greater confidence.”

Rising global cases of respiratory diseases, including lung cancer and COPD, are accelerating the adoption of AI-driven digital twin technologies. These innovations are expected to shift clinical workflows away from conventional imaging interpretation toward predictive, simulation-led, and minimally invasive intervention planning, supporting more personalized and data-driven treatment strategies.

Under the agreement, Daiichi will obtain exclusive rights to the tool, known as lipodia, representing what could become the company’s first step in extending its cardiovascular portfolio into the digital health sector. The initial rollout of the partnership will focus on the German healthcare market, although the company intends to expand lipodia’s reach to “all major markets on the continent.” The digital solution works by integrating patient-specific, evidence-based behavioural health and psychotherapeutic strategies that guide users toward long-term lifestyle adjustments. Designed to complement pharmaceutical therapy, the system aims to encourage sustained behavioural change while helping reduce a patient’s risk of cardiovascular disease (CVD).

“Digital therapeutics represent an important next step in delivering holistic heart health,” said Oliver Appelhans, Daiichi’s head of EU speciality business. “By combining pharmaceuticals with evidence-based digital therapeutics, we can support patients beyond our medicines.” To support wider access to the therapy, GAIA intends to submit a reimbursement application for lipodia once results from its pivotal Phase III trial become available. Should the application receive approval, Germany’s public health insurers would reimburse the therapy through the country’s Digital Health Applications (DiGA) pathway.

The move reflects a broader trend in the pharmaceutical industry as companies explore how digital technologies can complement drug therapies. Although medications used to treat CVD have significantly improved outcomes, pharmacological treatments alone often do not address the behavioural changes needed for long-term prevention. Estimates suggest that around 80% of heart disease and stroke cases affecting European patients are preventable, highlighting the potential impact of early interventions and educational programmes designed to encourage sustained lifestyle changes. As a result, several pharmaceutical companies are evaluating ways to combine digital health tools and patient education platforms with existing therapies.

Activity in the cardiometabolic health segment illustrates this shift. Novo Nordisk has been exploring collaborations with digital health providers that could offer fitness and dietary guidance alongside treatment with its weight-loss medicine Wegovy (semaglutide). Meanwhile, Otsuka Pharmaceutical currently holds 16% of global revenue in regulator-approved digital health apps. Part of this position is supported by Rejoyn, an application developed with Click Therapeutics and launched in 2024 for patients with depression. The app works alongside the company’s pharmaceutical treatments for major depressive disorder (MDD), including Rexulti (brexpiprazole) and Abilify (aripiprazole).

According to recent analysis from GlobalData, regulator-approved applications are playing a central role in driving growth across the digital health segment, which remains “still in its early stages.” Regulators are also moving to facilitate wider adoption of these technologies. Both the US Food and Drug Administration (FDA) and the UK’s Medicines and Healthcare products Regulatory Authority (MHRA) have introduced policies aimed at encouraging the broader use of digital health tools throughout healthcare systems.

Through the integration, physicians will be able to use natural language queries to search for and retrieve up-to-date clinical data. According to the organizations, the system is built to support quality and safety standards while streamlining how doctors access relevant medical information during patient encounters.

Laura Wilt, Sutter Health’s chief digital officer, said the collaboration reflects a shared ambition to strengthen clinical support and reshape care delivery. She described the effort as part of a broader transformation agenda. “It’s how we’re transforming the way we serve patients, support care teams and improve outcomes,” she said. Wilt added that the organizations are aligned in their commitment to “reimagining healthcare for the better.”

The deployment builds on Sutter Health’s earlier investments in generative AI. Two years ago, the California health system began using generative AI tools with the goal of reducing clinician burnout and enhancing organizational sustainability. At that time, Dr. Albert Chan, Sutter Health’s chief health information officer, said in a statement that the generative AI platform enabled providers to “recharge.”

OpenEvidence, for its part, said the collaboration is intended to move the needle on healthcare sustainability and medical AI safety. Dr. Travis Zack, OpenEvidence’s chief medical officer, indicated that working with Sutter Health advances those objectives.

Clinical decision support has long been associated with improved patient outcomes and more efficient resource utilization. More recently, scientific research has examined whether emerging generative AI technologies can further strengthen performance. Last year, researchers at Mass General Brigham evaluated a hybrid strategy over the course of a yearlong study.

The team compared two large language models (LLMs) – OpenAI’s GPT-4 and Google’s Gemini 1.5 – against the health system’s diagnostic decision support system, DXplain. Findings showed that the established, homegrown platform surpassed the LLMs in diagnostic accuracy for patient cases. However, researchers concluded that combining AI capabilities with traditional decision support systems could yield stronger results.

In their report, the MGB researchers detailed how pairing DXplain with an LLM could enhance the clinical efficacy of both systems. “A hybrid approach that combines the parsing and expository linguistic capabilities of LLMs with the deterministic and explanatory capabilities of traditional DDSSs may produce synergistic benefits,” they said.

Sutter Health executives framed the OpenEvidence integration as part of a broader digital strategy. “Digital innovation plays a central role in our work to build a more connected, proactive and sustainable healthcare system,” Wilt said in the announcement. Dr. Ashley Beecy, Sutter Health’s chief AI officer, underscored the patient impact, stating, “Patients benefit when providers have the most current and relevant evidence incorporated into clinical decision-making,” she added.

The fast track pathway is intended to speed up the development and regulatory review of therapies and diagnostic tools that target serious conditions and address unmet medical needs. Interstitial lung disease encompasses more than 200 disorders that compromise lung function and are characterised by progressive inflammation, fibrosis and a gradual deterioration in quality of life. In clinical practice, distinguishing between inflammatory activity and fibrotic damage at an early stage is critical for guiding treatment decisions. However, achieving that differentiation remains highly challenging.

With fast track status in place, Serac Healthcare may benefit from a range of regulatory mechanisms designed to reduce the time required for approval in the United States. These include potential eligibility for accelerated approval and priority review. The designation also enables more frequent meetings and written correspondence with the FDA, alongside the option for rolling review of sections of a new drug application as they are finalised.

David Hail, Chief Executive Officer of Serac Healthcare, said: ‘‘The FDA’s Fast Track designation of maraciclatide signals the imperative for improved ILD diagnosis, assessment, and monitoring. ILD symptoms are non-specific and often present late in disease progression, making early detection extremely difficult.

“While symptom management therapies are available, including powerful anti-inflammatory agents, inappropriate administration can prove more detrimental than beneficial. A non-invasive imaging solution capable of distinguishing inflammation and fibrosis predominant ILD has the potential to meaningfully advance early diagnosis, change the treatment paradigm and improve patient outcomes.’’

99mTc-maraciclatide functions as a radiolabelled tracer with high affinity binding to αvβ3 integrin. This cell-adhesion molecule is up-regulated in vascular endothelial cells during angiogenesis, a biological process central to inflammation.

Early findings from the PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD) trial, based on preliminary phase 2 data, suggest that the agent may enable visualisation of inflammation in patients with fibrotic ILD. Additional clinical results are anticipated later this year.

Previously known as the Rules Based Pathway, National Healthtech Access Programme establishes a coordinated framework between NICE, the Department of Health and Social Care, NHS England, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Office for Life Sciences. Under the new structure, NICE will incorporate selected health technologies into its Technology Appraisals programme alongside medicines placing medical devices, diagnostics and digital health tools within the same national appraisal mechanism.

The move addresses longstanding concerns that cutting-edge HealthTech has not been used in the NHS or has only been available to patients in some parts of the country. By subjecting eligible technologies to formal cost-benefit analysis, NICE will determine whether they are clinically and cost-effective for nationwide adoption. Approved technologies will be reimbursed and made available consistently across the NHS.

Professor Jonathan Benger, Chief Executive of NICE, said: “When NICE was founded 26 years ago, it set out to end the postcode lottery in access to medicines. We’re now extending that same clarity and fairness to HealthTech. These reforms mean that clinically and cost-effective medical devices, diagnostics and digital tools will start to be reimbursed and made available consistently across the NHS. This will give patients faster access to proven technologies and ensure NHS resources are spent where they make the greatest difference.”

Initial technologies prioritised under NHAP

The first two technologies entering the pathway are capsule sponge tests for detecting oesophageal cancer and AI tools for identifying prostate and breast cancer. Ministers have also referred two additional oncology diagnostics for potential review: technologies to improve detection of endometrial cancer in women with unexplained vaginal bleeding, and AI-supported chest X-ray analysis for suspected lung cancer in primary care referrals.

Oesophageal cancer is often diagnosed too late, leading to poor outcomes and significant pressure on NHS diagnostic services. Early-stage disease has a 95% five-year survival rate, compared with 5–40% when diagnosed at an advanced stage. The capsule sponge test sometimes called a “pill on a string” offers a less invasive alternative to endoscopy for the early detection of oesophageal cancer and the surveillance of Barrett’s oesophagus.

The procedure involves a patient swallowing a dissolvable capsule containing a compressed sponge under the supervision of a healthcare professional, without the need for sedation. Once in the stomach, the capsule dissolves and the sponge expands. The device is then withdrawn using an attached string, collecting oesophageal cells for laboratory testing to identify abnormal or potentially cancerous cells. The method supports earlier diagnosis and helps free endoscopy capacity for urgent investigations.

Alongside this, AI pathology tools selected for review analyse images of tissue samples to support diagnosis in prostate and breast cancer two of the NHS’s largest caseload areas. The algorithms highlight suspicious regions, grade tumours and support pathologists by reducing routine workload, improving consistency and enabling faster prioritisation of high-risk cases.

Reported system-wide benefits include increasing accuracy, standardisation and reporting speed; supporting the NHS Faster Diagnosis framework and ambitions for AI adoption in cancer pathways in its Long Term Plan; reducing workforce pressures by automating routine tasks; supporting national cancer targets; reducing diagnostic bottlenecks; improving throughput; and potentially reducing inequalities in time to diagnosis linked to geography, deprivation and variation in access to specialist pathology expertise.

Policy alignment and regulatory context

NHAP sits within the broader 10 Year Health Plan for England, which aims to address the long-standing challenge that innovative HealthTech has not been used consistently across the NHS. The plan sets out a shift towards preventative care supported by earlier diagnosis and screening through the use of technology.

The programme is one of three commitments NICE will deliver under the 10 Year Plan: faster and fairer rollout of high-impact HealthTech; updating guidance to drive smarter spending; and parallel decisions to enable faster access.

The policy direction reflects wider regulatory engagement with health technologies, particularly artificial intelligence. In September 2025, the MHRA introduced an AI Commission to address regulatory uncertainty around the technology and encourage its safe and effective use in the wider healthcare sector. Internationally, the US Food and Drug Administration (FDA) has been encouraging the development of AI-enabled medical devices aligned with regulatory expectations as it looks to employ the technology within its own workflow.

By expanding NICE’s appraisal programme to incorporate selected health technologies and linking approval to national reimbursement, NHAP establishes a structured mechanism for evaluating and making available clinically and cost-effective devices, diagnostics and digital tools across the NHS.

The CE mark for NeVa VS introduces an alternative treatment option for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cerebral vasospasm occurs when blood vessels in the brain become narrowed and constricted, typically in the days or weeks after a ruptured brain aneurysm (subarachnoid hemorrhage). This narrowing can significantly restrict oxygen delivery to brain tissue, increasing the risk of brain damage and, in severe cases, death without timely intervention.

NeVa VS is a novel self-expanding, retractable nitinol-based cerebral dilation device that preserves distal blood flow while treating the narrowed vessels. Its braided stent architecture reinforces vessel integrity while maintaining continuous circulation, positioning it as a safer alternative to balloon angioplasty. Early clinical data showed 93.2% of NeVa VS-treated vessels required no further intervention.

The device has already gained FDA approval under a Humanitarian Device Exemption.

Alongside NeVa VS, Vesalio also received CE mark certification for NeVa 3.0 mm. This stent builds on Vesalio’s patented neuro thrombectomy technology and is specifically designed to address smaller, more tortuous arteries.

Vesalio’s NeVa stent portfolio is engineered to retrieve blood clots in a single pass by entrapping and securing the clot within one of three braided net sections. This approach differs from traditional endovascular thrombectomy methods that penetrate the clot, pin it, and drag it along the artery wall for removal.

NeVa 3.0 mm enables clot retrieval in arteries as small as 1.5 mm, expanding the number of patients who may be eligible for mechanical thrombectomy.

“These approvals mark our seventh CE certification and reflect the continued growth and strategic refinement of Vesalio’s neurovascular portfolio on a global scale,” said Vesalio VP of Market Development, Diane Demet Tangun.

Following CE mark certification, Vesalio confirmed the European commercial launch of NeVa VS and NeVa 3.0 mm, further strengthening its portfolio of neurovascular devices from Vesalio available in the region.

Separately, the company also obtained 510(k) clearance to expand indications to include distal access with microcatheter delivery in its neurovascular and peripheral aspiration catheters. Distal access with microcatheter delivery can help improve visualization of brain aneurysms hidden by adjacent arteries or branches.

CMS said the companies intend to help states prepare for and roll out Medicaid community engagement and work requirements by providing technology products and services tied to eligibility, enrollment, verification, and system modernization. Each company already holds Medicaid eligibility and enrollment contracts with states, allowing for faster deployment. CMS stated the voluntary commitments are expected to reduce costs for states and taxpayers while improving the beneficiary experience.

The participating companies include Accenture, Acentra Health, Conduent, General Dynamics Information Technology, Deloitte, Gainwell, Maximus, Curam by Merative, Optum, and RedMane.

“Gainwell is proud to join the Centers for Medicare and Medicaid Services and our industry peers in supporting states as they implement Medicaid community engagement requirements. This pledge reflects our commitment to advancing federal and state policy goals, modernizing Medicaid systems through purposeful public–private collaboration, and addressing fraud, waste, and abuse,” Gainwell said by statement. “The Gainwell Community Engagement Verification solution combines decades of Medicaid and verification expertise with modern AI technology to help states meet federal requirements quickly and efficiently, strengthen member engagement and reduce administrative burden. The solution is designed to flexibly meet states where they are. It is offered at a low price point, and built for rapid deployment and seamless integration.”

CMS also said it is working with the General Services Administration to enable vendors to obtain GSA Schedule access, allowing states to procure technology solutions more quickly. Additional efforts include expanding testing environments, aligning eligibility system changes, and supporting automated, consent-based data verification.

States are required to implement Medicaid work requirements by January 1, 2027, under President Donald Trump’s Working Families Tax Cut legislation. CMS said the requirements are intended to support adult beneficiaries through employment, education, volunteering, or job training.

Since enactment of the law, CMS has issued guidance, conducted state outreach, tested beneficiary engagement tools, and developed an open-source platform called EMMY to streamline eligibility determinations and verification workflows. These initiatives are designed to minimize administrative burden while improving system readiness and compliance with Medicaid work requirements.

“Community engagement provides dignity and purpose,” said Health and Human Services Secretary Robert F. Kennedy, Jr. “Thanks to [CMS Administrator] Dr. [Mehmet] Oz’s leadership, we’re one step closer to delivering President Trump’s vision of bringing every able-bodied adult on Medicaid into the workforce and other cornerstones of society.”

“From the outset, our focus has been on helping states implement these requirements efficiently while supporting new innovations in Medicaid that improve the beneficiary experience,” said Dan Brillman, director of the Center for Medicaid and CHIP Services. “We applaud vendors for their voluntary commitments and discounting their solutions, providing states with additional options as they plan their implementation and modernize their Medicaid systems.”

Allia Moveo is the latest member of GE HealthCare’s Allia line and was announced at the Radiological Society of North America’s 2025 annual meeting. Created for cardio, vascular, nonvascular, interventional, and surgical procedures, Allia Moveo merges a small form factor, cable-free C-arm with AI-assisted imaging and guidance technology.

GE HealthCare said that the system will free up space in interventional suites with its portability, quiet mobility system, and intuitive controls. These benefits aim to simplify workflows during minimally invasive procedures, which can involve numerous clinicians and imaging equipment.

The first global installation was completed at Hôpital Marie-Lannelongue, a national reference center for complex aortic disease. The hospital plans to use the system for vascular and cardiology procedures, including cone-beam computed tomography imaging. Its wide-bore design and flexible table movement are designed to accommodate patients of varying body size and weight while improving access for care teams.

“With Allia Moveo, we had this opportunity to position the system very quickly in any working position that will adapt the best to us,” said Stephan Haulon, head of the Aortic Center and Vascular Surgery at Hôpital Marie-Lannelongue. “One of the major milestones of this new system is having access to the reconstruction of the cone beam CT with CleaRecon DL, which is AI driven and gives you much better image quality.”

GE HealthCare stated that the system was developed through close collaboration with clinicians as procedures become more complex and interventional suite space becomes more limited.

“With Allia Moveo, we’re elevating the clinician experience, removing complexity, accelerating workflow, and enabling greater control during procedures,” said Arnaud Marie, general manager of interventional solutions at GE HealthCare. “We are excited to collaborate with leading experts at Hôpital Marie-Lannelongue on the first installation of this system, which is a defining step forward for care in the interventional suite, and a testament to our shared commitment to advancing meaningful innovation with the goal of supporting better outcomes for care teams and the patients they treat.”

Following the initial installation in France, Baylor St. Luke’s Medical Center became the first U.S. hospital to deploy the platform, extending GE HealthCare FDA clearance into clinical practice in the United States.

“We are honored to be the first hospital in the United States to install Allia Moveo, and proud to help advance the next generation of interventional care,” said Brad Lembke, president of Baylor St. Luke’s Medical Center. “This innovative platform enhances how our clinicians navigate complex minimally invasive procedures by improving mobility, image clarity, and workflow efficiency. It strengthens our ability to deliver precise, patient-centered care while supporting our teams with technology designed for the evolving demands of modern interventional medicine.”